Urokinase Plasminogen Activator Receptor: An Important Focal Player in Chronic Subdural Hematoma?
H-score.
chronic subdural hematoma
histology
luminex
pathophysiology
recurrence
recurrent CSDH
urokinase plasminogen activator surface receptor
Journal
Inflammation
ISSN: 1573-2576
Titre abrégé: Inflammation
Pays: United States
ID NLM: 7600105
Informations de publication
Date de publication:
18 Jan 2024
18 Jan 2024
Historique:
received:
01
12
2023
accepted:
23
12
2023
revised:
18
12
2023
medline:
18
1
2024
pubmed:
18
1
2024
entrez:
18
1
2024
Statut:
aheadofprint
Résumé
Chronic subdural hematoma (CSDH) development involves inflammatory, angiogenetic, and fibrinolytic mechanisms, several components of which are now unraveled through intensive research. The urokinase plasminogen activator receptor (uPAR) is part of the plasminogen activator system and possesses inflammatory, angiogenetic, and fibrinolytic capabilities. As a first, this study aims to identify uPAR in the hematoma fluid, hematoma membrane, dura mater, and systemic blood from patients with CSDH and, if present, to investigate if the uPAR level at the time of surgery may be a predictor for later developing recurrent CSDH. uPAR expression in the hematoma membrane and dura mater was analyzed using immunohistochemistry and presented as the H-score of the positive immunostaining. The uPAR levels in the hematoma fluid and systemic blood were determined using a multiplex antibody bead kit (Luminex). Samples were collected at the time of the first CSDH surgery, and in the case of recurrent CSDH within 90 days, the samples were again collected at reoperation. A comparison of uPAR expression between the hematoma membrane and dura mater, as well as uPAR levels in systemic blood and hematoma fluid, was performed using the Wilcoxon rank sum test. We included 112 patients, 26 of whom had recurrent CSDH. The median hematoma uPAR level was 22,125 (14,845-33,237) and significantly higher than the median systemic blood level of 789 pg/L (465-2,088) (p < 0.001). Similarly, the uPAR level of the hematoma membrane was 14.3 (7.54-44.8) and significantly higher than the dural uPAR level of 0.81 (0.3-1.98) (p < 0.001). For the first time, we identified uPAR in the subdural fluid, hematoma membrane, dura mater, and systemic blood from patients with CSDH. The high expression of uPAR in the subdural fluid and hematoma membrane indicates that the mechanisms of CSDH are predominantly in the subdural fluid collection and surrounding hematoma membrane.
Identifiants
pubmed: 38236383
doi: 10.1007/s10753-023-01957-5
pii: 10.1007/s10753-023-01957-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : ERC Advanced Grant
ID : 670261
Organisme : the Danish National Research Foundation
ID : 126
Informations de copyright
© 2024. The Author(s).
Références
Edlmann, E., S. Giorgi-Coll, P.C. Whitfield, K.L.H. Carpenter, and P.J. Hutchinson. 2017. Pathophysiology of chronic subdural haematoma: Inflammation, angiogenesis and implications for pharmacotherapy. Journal of Neuroinflammation 14 (1): 108.
pubmed: 28558815
pmcid: 5450087
doi: 10.1186/s12974-017-0881-y
Ploug, M., E. Rønne, N. Behrendt, A. L. Jensen, F. Blasi, and K. Danø. 1991. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. Journal of Biological Chemistry 266(3):1926–1933.
Smith, H.W., and C.J. Marshall. 2010. Regulation of cell signalling by uPAR. Nature Reviews Molecular Cell Biology. 11 (1): 23–36.
pubmed: 20027185
doi: 10.1038/nrm2821
Mondino, A., and F. Blasi. 2004. uPA and uPAR in fibrinolysis, immunity and pathology. Trends in Immunology 25 (8): 450–455.
pubmed: 15275645
doi: 10.1016/j.it.2004.06.004
Dinesh, P., and M. Rasool. 2018. uPA/uPAR signaling in rheumatoid arthritis: Shedding light on its mechanism of action. Pharmacological Research 134: 31–39.
pubmed: 29859810
doi: 10.1016/j.phrs.2018.05.016
Boonstra, M.C., H.W. Verspaget, S. Ganesh, F.J. Kubben, A.L. Vahrmeijer, C.J. van de Velde, et al. 2011. Clinical applications of the urokinase receptor (uPAR) for cancer patients. Current Pharmaceutical Design 17 (19): 1890–1910.
pubmed: 21711239
doi: 10.2174/138161211796718233
Baart, V.M., R.D. Houvast, L.F. de Geus-Oei, P.H.A. Quax, P.J.K. Kuppen, A.L. Vahrmeijer, et al. 2020. Molecular imaging of the urokinase plasminogen activator receptor: Opportunities beyond cancer. EJNMMI Research 10 (1): 87.
pubmed: 32725278
pmcid: 7387399
doi: 10.1186/s13550-020-00673-7
Zhang, J., S. Sud, K. Mizutani, M.R. Gyetko, and K.J. Pienta. 2011. Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model. Neoplasia 13 (1): 23–30.
pubmed: 21245937
pmcid: 3022425
doi: 10.1593/neo.10728
Raghu, H., A.K. Nalla, C.S. Gondi, M. Gujrati, D.H. Dinh, and J.S. Rao. 2012. uPA and uPAR shRNA inhibit angiogenesis via enhanced secretion of SVEGFR1 independent of GM-CSF but dependent on TIMP-1 in endothelial and glioblastoma cells. Molecular Oncology 6 (1): 33–47.
pubmed: 22177802
doi: 10.1016/j.molonc.2011.11.008
Hohenstein, A., R. Erber, L. Schilling, and R. Weigel. 2005. Increased mRNA expression of VEGF within the hematoma and imbalance of angiopoietin-1 and -2 mRNA within the neomembranes of chronic subdural hematoma. Journal of Neurotrauma 22 (5): 518–528.
pubmed: 15892598
doi: 10.1089/neu.2005.22.518
Charlson, M.E., D. Carrozzino, J. Guidi, and C. Patierno. 2022. Charlson comorbidity index: A critical review of clinimetric properties. Psychotherapy and Psychosomatics 91 (1): 8–35.
pubmed: 34991091
doi: 10.1159/000521288
Zhou, Y., Z. Xu, and Z. Liu. 2023. Role of IL-33-ST2 pathway in regulating inflammation: Current evidence and future perspectives. Journal of Translational Medicine 21 (1): 902.
pubmed: 38082335
pmcid: 10714644
doi: 10.1186/s12967-023-04782-4
Crotty, K., P. Anton, L.G. Coleman, N.L. Morris, S.A. Lewis, D.R. Samuelson, et al. 2023. A critical review of recent knowledge of alcohol’s effects on the immunological response in different tissues. Alcohol Clin Exp Res (Hoboken). 47 (1): 36–44.
pubmed: 36446606
doi: 10.1111/acer.14979
Franco, C., E. Sciatti, G. Favero, F. Bonomini, E. Vizzardi, R. Rezzani. 2022. Essential Hypertension and Oxidative Stress: Novel Future Perspectives. International Journal of Molecular Sciences 23 (22).
Herrera-Martínez, A.D., V. Herrero-Aguayo, J.M. Pérez-Gómez, M.D. Gahete, and R.M. Luque. 2022. Inflammasomes: Cause or consequence of obesity-associated comorbidities in humans. Obesity (Silver Spring) 30 (12): 2351–2362.
pubmed: 36415999
doi: 10.1002/oby.23581
Aasarey, R., K. Yadav, B.K. Kashyap, S. Prabha, P. Kumar, A. Kumar, et al. 2023. Role of immunological cells in hepatocellular carcinoma disease and associated pathways. ACS Pharmacol Transl Sci. 6 (12): 1801–1816.
pubmed: 38093838
doi: 10.1021/acsptsci.3c00216
Sucu, H.K., M. Gokmen, and F. Gelal. 2005. The value of XYZ/2 technique compared with computer-assisted volumetric analysis to estimate the volume of chronic subdural hematoma. Stroke 36 (5): 998–1000.
pubmed: 15817899
doi: 10.1161/01.STR.0000162714.46038.0f
Jensen, T.S.R., N. Andersen-Ranberg, F.R. Poulsen, B. Bergholt, T. Hundsholt, and K. Fugleholm. 2020. The Danish Chronic Subdural Hematoma Study-comparison of hematoma age to the radiological appearance at time of diagnosis. Acta Neurochirurgica. Supplementum 162 (9): 2007–2013.
doi: 10.1007/s00701-020-04472-w
Bankhead, P., M.B. Loughrey, J.A. Fernández, Y. Dombrowski, D.G. McArt, P.D. Dunne, et al. 2017. QuPath: Open source software for digital pathology image analysis. Science and Reports 7 (1): 16878.
doi: 10.1038/s41598-017-17204-5
Goulding, H., S. Pinder, P. Cannon, D. Pearson, R. Nicholson, D. Snead, et al. 1995. A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples. Human Pathology 26 (3): 291–294.
pubmed: 7890280
doi: 10.1016/0046-8177(95)90060-8
Swets, J.A. 1988. Measuring the accuracy of diagnostic systems. Science 240 (4857): 1285–1293.
pubmed: 3287615
doi: 10.1126/science.3287615
Hutchinson, P.J., E. Edlmann, D. Bulters, A. Zolnourian, P. Holton, N. Suttner, et al. 2020. Trial of dexamethasone for chronic subdural hematoma. New England Journal of Medicine 383 (27): 2616–2627.
pubmed: 33326713
doi: 10.1056/NEJMoa2020473
Nathoo, N., A. Chahlavi, G.H. Barnett, and S.A. Toms. 2005. Pathobiology of brain metastases. Journal of Clinical Pathology 58 (3): 237–242.
pubmed: 15735152
pmcid: 1770599
doi: 10.1136/jcp.2003.013623
Bindal, A.K., M. Hammoud, W.M. Shi, S.Z. Wu, R. Sawaya, and J.S. Rao. 1994. Prognostic significance of proteolytic enzymes in human brain tumors. Journal of Neuro-oncology 22 (2): 101–110.
pubmed: 7538161
doi: 10.1007/BF01052886
Risør, L.M., T. Binderup, M. Fosbøl, K.F. Andersen, A. Loft, J. Friborg, et al. 2022. Urokinase-type plasminogen activator receptor (uPAR) assessed by liquid biopsies and PET/CT for prognostication in head and neck cancer patients. Science and Reports 12 (1): 19126.
doi: 10.1038/s41598-022-21175-7
Lawaetz, M., T. Binderup, A. Christensen, K. Juhl, G. Lelkaitis, E. Lykke. et al. 2023. Urokinase-type plasminogen activator receptor (uPAR) expression and [(64)Cu]Cu-DOTA-AE105 uPAR-PET/CT in patient-derived xenograft models of oral squamous cell carcinoma. Molecular Imaging Biology
Gabay, C., and I. Kushner. 1999. Acute-phase proteins and other systemic responses to inflammation. New England Journal of Medicine 340 (6): 448–454.
pubmed: 9971870
doi: 10.1056/NEJM199902113400607
Beschorner, R., H.J. Schluesener, T.D. Nguyen, V. Magdolen, T. Luther, I. Pedal, et al. 2000. Lesion-associated accumulation of uPAR/CD87- expressing infiltrating granulocytes, activated microglial cells/macrophages and upregulation by endothelial cells following TBI and FCI in humans. Neuropathology and Applied Neurobiology 26 (6): 522–527.
pubmed: 11123718
doi: 10.1046/j.0305-1846.2000.287.x
Cinque, P., M. Nebuloni, M.L. Santovito, R.W. Price, M. Gisslen, L. Hagberg, et al. 2004. The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations. Annals of Neurology 55 (5): 687–694.
pubmed: 15122709
doi: 10.1002/ana.20076
Deininger, M.H., K. Trautmann, V. Magdolen, T. Luther, H.J. Schluesener, and R. Meyermann. 2002. Cortical neurons of Creutzfeldt-Jakob disease patients express the urokinase-type plasminogen activator receptor. Neuroscience Letters 324 (1): 80–82.
pubmed: 11983300
doi: 10.1016/S0304-3940(02)00168-4
Fauser, S., M.H. Deininger, P.G. Kremsner, V. Magdolen, T. Luther, R. Meyermann, et al. 2000. Lesion associated expression of urokinase-type plasminogen activator receptor (uPAR, CD87) in human cerebral malaria. Journal of Neuroimmunology 111 (1–2): 234–240.
pubmed: 11063844
doi: 10.1016/S0165-5728(00)00368-4
Gveric, D., R. Hanemaaijer, J. Newcombe, N.A. van Lent, C.F. Sier, and M.L. Cuzner. 2001. Plasminogen activators in multiple sclerosis lesions: Implications for the inflammatory response and axonal damage. Brain 124 (Pt 10): 1978–1988.
pubmed: 11571216
doi: 10.1093/brain/124.10.1978
Sidenius, N., M. Nebuloni, S. Sala, P. Zerbi, R.W. Price, M. Gisslen, et al. 2004. Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease. Journal of Neuroimmunology 157 (1–2): 133–139.
pubmed: 15579290
doi: 10.1016/j.jneuroim.2004.08.038
Walker, D.G., L.F. Lue, and T.G. Beach. 2002. Increased expression of the urokinase plasminogen-activator receptor in amyloid beta peptide-treated human brain microglia and in AD brains. Brain Research 926 (1–2): 69–79.
pubmed: 11814408
doi: 10.1016/S0006-8993(01)03298-X
Breuss, J.M., and P. Uhrin. 2012. VEGF-initiated angiogenesis and the uPA/uPAR system. Cell Adhesion & Migration 6 (6): 535–615.
doi: 10.4161/cam.22243
Rao, J.S., M. Gujrati, C. Chetty. 2013. Tumor-associated soluble uPAR-directed endothelial cell motility and tumor angiogenesis. Oncogenesis 2 (6): e53
Høyer-Hansen, G., M. Ploug, N. Behrendt, E. Rønne, and K. Danø. 1997. Cell-surface acceleration of urokinase-catalyzed receptor cleavage. European Journal of Biochemistry 243 (1–2): 21–26.
pubmed: 9030717
doi: 10.1111/j.1432-1033.1997.0021a.x
Sidenius, N., A. Andolfo, R. Fesce, and F. Blasi. 2002. Urokinase regulates vitronectin binding by controlling urokinase receptor oligomerization. Journal of Biological Chemistry 277 (31): 27982–27990.
pubmed: 12034711
doi: 10.1074/jbc.M111736200
Herz, J., and D.K. Strickland. 2001. LRP: A multifunctional scavenger and signaling receptor. The Journal of Clinical Investigation 108 (6): 779–784.
pubmed: 11560943
pmcid: 200939
doi: 10.1172/JCI200113992
Sappino, A.P., R. Madani, J. Huarte, D. Belin, J.Z. Kiss, A. Wohlwend, et al. 1993. Extracellular proteolysis in the adult murine brain. The Journal of Clinical Investigation 92 (2): 679–685.
pubmed: 8349806
pmcid: 294901
doi: 10.1172/JCI116637
Tseng, J.H., M.Y. Tseng, A.J. Liu, W.H. Lin, H.Y. Hu, and S.H. Hsiao. 2014. Risk factors for chronic subdural hematoma after a minor head injury in the elderly: A population-based study. BioMed Research International 2014: 218646.
pubmed: 25295251
pmcid: 4180895
doi: 10.1155/2014/218646
Jensen, T.S.R., N. Andersen-Ranberg, F.R. Poulsen, B. Bergholt, T. Hundsholt, and K. Fugleholm. 2022. The Danish chronic subdural hematoma study-risk factors for second recurrence. World Neurosurg. 168: e178–e186.
pubmed: 36152937
doi: 10.1016/j.wneu.2022.09.072
Jensen, T.S.R., T. Binderup, M.H. Olsen, A. Kjaer, K. Fugleholm. 2023. Subdural levels of interleukin 1-receptor antagonist are elevated in patients with recurrent chronic subdural hematomas. Inflammation
de Oliveira, A.J.M., D.J.F. Solla, K.F. de Oliveira, B.S. Amaral, A.F. Andrade, A.G. Kolias, et al. 2022. Postoperative neutrophil-to-lymphocyte ratio variation is associated with chronic subdural hematoma recurrence. Neurological Sciences 43 (1): 427–434.
pubmed: 33891187
doi: 10.1007/s10072-021-05241-y
Saul, H., D. Gursul, S. Cassidy, P. Hutchinson, and A. Kolias. 2022. Dexamethasone should not be given to people with a chronic subdural haematoma. BMJ 377: o1302.
pubmed: 35688460
doi: 10.1136/bmj.o1302
Mori, K., and M. Maeda. 2001. Surgical treatment of chronic subdural hematoma in 500 consecutive cases: Clinical characteristics, surgical outcome, complications, and recurrence rate. Neurologia Medico-Chirurgica (Tokyo) 41 (8): 371–381.
doi: 10.2176/nmc.41.371
Tseng, J.-H., M.-Y. Tseng, A.-J. Liu, W.-H. Lin, H.-Y. Hu, and S.-H. Hsiao. 2014. Risk factors for chronic subdural hematoma after a minor head injury in the elderly: A population-based study. BioMed Research International. 2014: 218646.
pubmed: 25295251
pmcid: 4180895
doi: 10.1155/2014/218646
Lee, J.J., Y. Won, T. Yang, S. Kim, C.S. Choi, and J. Yang. 2015. Risk factors of chronic subdural hematoma progression after conservative management of cases with initially acute subdural hematoma. Korean J Neurotrauma. 11 (2): 52–57.
pubmed: 27169065
pmcid: 4847520
doi: 10.13004/kjnt.2015.11.2.52
Jack, A., C. O’Kelly, C. McDougall, and J.M. Findlay. 2015. Predicting recurrence after chronic subdural haematoma drainage. Canadian Journal of Neurological Sciences 42 (1): 34–39.
doi: 10.1017/cjn.2014.122
Shen, J., L. Yuan, R. Ge, Q. Wang, W. Zhou, X.C. Jiang, et al. 2019. Clinical and radiological factors predicting recurrence of chronic subdural hematoma: A retrospective cohort study. Injury 50 (10): 1634–1640.
pubmed: 31445831
doi: 10.1016/j.injury.2019.08.019
Andersen-Ranberg, N.C., F.R. Poulsen, B. Bergholt, T. Hundsholt, and K. Fugleholm. 2017. Bilateral chronic subdural hematoma: Unilateral or bilateral drainage? Journal of Neurosurgery 126 (6): 1905–1911.
pubmed: 27392267
doi: 10.3171/2016.4.JNS152642